“If the data trail is not inspectable at submission, the asset value is not what the board thinks it is.”

Lauren Alani

If a regulatory inspector and a Big-Pharma due-diligence partner walked into the same sponsor on the same day, both would ask the data team for the same set of things. Source documents. Edit-check logic. Audit trails. Data lineage. Evidence of validation. Evidence of oversight. Change control records. Discrepancy logs. Their reasons differ. Their lists do not.

This is the underappreciated truth about clinical data integrity. The same artefacts that make a trial inspection-defensible also make an asset deal-defensible. Sponsors who treat data integrity as a regulatory hygiene exercise produce documents the regulator may grudgingly accept and the investor’s diligence team will not. Sponsors who treat it as commercial risk produce documents that work for both audiences.

The regulatory floor: ALCOA+

The regulatory framing of data integrity is well established. ALCOA, articulated by FDA in the 1990s, sets the principles: Attributable, Legible, Contemporaneous, Original, Accurate. The “+” extension adds Complete, Consistent, Enduring, and Available. EMA’s reflection paper on computerised systems and ICH GCP E6(R3) both anchor expectations to these principles.

ALCOA+ is the floor. It defines what minimally acceptable data evidence looks like. A trial that meets ALCOA+ has data that can be traced to its source, read without ambiguity, recorded at the time of the event, retained in original form, and demonstrated to be accurate. The records are complete, internally consistent, retrievable years after the trial closes, and accessible when an inspector or auditor asks.

Many sponsors treat ALCOA+ as a quality team’s checklist. The data team produces evidence; the quality team verifies it; the inspector accepts it. The framing is operational, narrow, and bounded to the trial. That framing is regulatorily sufficient. It is commercially insufficient.

The commercial ceiling: asset defensibility

Investors and acquirers do not buy clinical trials. They buy assets, defined by their data. The Phase 2 readout. The biomarker analysis. The dose-finding study. The pivotal trial. Each of these is, in commercial-asset terms, a body of data with claims attached. The credibility of the claims rests on the credibility of the data. The credibility of the data rests on its integrity.

The danger of that assumption (that ALCOA+ compliance equals commercial credibility) is that compliance and credibility share evidence but ask different questions of it.

An inspector asks: do these records meet regulatory expectations? An acquirer’s diligence team asks: would I bet a billion dollars on these records? The first question can be answered yes by records that are technically compliant but operationally fragile. The second question is harder, because diligence teams are looking for evidence of structural rigour, not just procedural conformance. They want to see that the sponsor was actively engaged in data quality, not just keeping documents tidy.

How weak data integrity actually destroys value

I am rarely asked to look at an asset that has imploded over a single catastrophic data finding. That happens, occasionally. It is not the typical pattern. The typical pattern is cumulative.

A diligence team reviews the trial dossier. They find a few minor inconsistencies in the audit trail. They find a vendor validation package that does not quite map to the sponsor’s configuration documents. They find oversight records that are present but thin. They find a change control log that has gaps in 2024. None of these is fatal. Together they form a picture: this sponsor’s data integrity discipline was patchy. The diligence team marks down the asset’s data quality risk score. The deal valuation moves. Sometimes by a few percent. Sometimes by enough to break the deal.

This is a quiet failure mode. It rarely makes a press release. It shows up in negotiated terms, in extended diligence periods, in additional conditions precedent, in side letters about indemnities. It also shows up, occasionally, in deals that simply do not happen, with the parties moving on to assets that read more credibly.

What “data integrity as commercial risk” looks like in practice

Reframing data integrity as commercial risk does not mean spending more, although it sometimes does. It means deciding earlier, asking harder questions of vendors and CROs, and building evidence trails that anticipate diligence as well as inspection.

Practical posture shifts I see in sponsors who do this well:

• Earlier oversight investment. Quality and data leadership engaged at protocol authoring, not just at trial start.
• Vendor selection that prioritises evidence quality. Not just feature parity. Validation evidence, audit trail granularity, and integration lineage are weighted heavily.
• Documented oversight cadence. Sponsor-led review of the data lifecycle on a regular schedule, with records that survive personnel changes.
• Risk-based escalation. Discrepancies are graded, escalated, and resolved in writing. Resolution evidence sits in the sponsor’s records, not the CRO’s.
• Submission readiness as continuous discipline. The trial dossier is structured to support both regulatory submission and commercial diligence from the day data starts flowing.

None of these are technical changes. They are leadership posture changes that produce technical evidence as a downstream consequence.

What this looks like for early-stage biotechs

Clinical-stage biotechs frequently object that this framing is for big pharma, not for them. They have lean teams, fast timelines, capital constraints. They cannot match Tier 1 pharma on data integrity infrastructure.

The inverse is closer to true. A clinical-stage biotech is, almost by definition, an asset-on-the-table for an eventual deal. The data is the asset. Diligence will, at some point, scrutinise it. Lean does not exempt; it focuses. The smaller the team, the more important it is that the few oversight artefacts produced are the right ones, structured to scale into a diligence-grade dossier without rework.

Pragmatically, this means a small sponsor needs fewer documents but demands more from each one. The data flow map needs to be accurate, signed off, and maintained. The vendor oversight log needs to be present and thin rather than absent and fat. The validation acceptance records need to be structured to be audit-and-diligence ready from the start. The cost is small at the start. The cost of the alternative compounds.

The closing question

If your most active trial were the subject of an unscheduled regulatory inspection on Monday and a partnership diligence call on Wednesday, would you produce the same set of evidence for both? If the answer is yes, your data integrity discipline is doing both jobs at once. If the answer is no, the gap is the work.

Continue reading: Accountability Cannot Be Delegated for the underlying principle that anchors all four perspectives. Requirements Before Selection for the procurement-stage discipline. The Regulator-Vendor Gap for the structural context. All four perspectives in the insights archive. To bring this perspective to a board, an investor briefing, or a partnership conversation, see media and booking.

Frequently asked

The post Data integrity is a commercial risk, not regulatory paperwork. appeared first on Lauren Alani.

“If you let the vendor define the scope of the selection conversation, you have already lost the objectivity of the decision.”

Lauren Alani

Most clinical technology selection processes I have observed run roughly like this. A sponsor identifies a need (eCOA, ePRO, EDC, IRT, eConsent, wearables, you name it). The clinical operations team requests demos from three or four vendors. Demos are shown, scored against a feature matrix, and compared on price. A vendor is selected. Implementation begins. The trial-specific requirements get translated into the chosen platform’s structure, often with friction, because the structure was not designed around this trial; it was designed around the vendor’s standard offering.

The sequence is reversed. The trial’s needs should drive the selection; the selection should not drive the trial’s design. When the order is reversed, the cost shows up later, sometimes much later, in mid-trial system changes, validation rework, oversight blind spots, and inspection findings nobody anticipated at procurement.

The vendor demo problem

Vendor demos are commercial artefacts. They are designed by the vendor’s product marketing team to showcase the platform’s strengths. They are not designed to expose its constraints in the context of a specific trial. The demo’s narrative is built around the use cases the vendor is best at; the trial’s needs may sit anywhere across that landscape, including in the corners the demo did not visit.

A sponsor team scoring a demo is, in effect, evaluating the vendor’s marketing team. That is not what it should be evaluating. It should be evaluating the platform’s fitness for the specific trial, against trial-level requirements the sponsor has authored independently of the demo. Without those requirements, the demo is the de facto specification, and the platform’s strengths become the trial’s structure.

The danger of that assumption is that the trial inherits the platform’s design choices, including the choices the trial would not have made on its own. Some are minor inconveniences. Others surface as oversight gaps months in.

What “requirements” actually means

Requirements, in this context, are not a feature checklist. A feature checklist asks: does this platform support electronic signatures, audit trail, multi-language, role-based access? Most reputable platforms tick most boxes. The checklist tells the sponsor very little about whether the platform fits the trial.

Requirements are the trial-specific articulation of what data must be captured, how it must move, what regulatory expectations it must meet, what oversight points the sponsor needs to evidence, and what integration touchpoints exist with other systems in the trial’s architecture. They derive from the protocol, the regulatory framework, the data flow, the sponsor’s quality system, and the realistic assumptions about how this trial will be run, by whom, in which countries, with which sites.

Authored well, a requirements document is 30 to 80 pages. It takes weeks to produce. It is signed off by the sponsor’s clinical, data management, regulatory, and quality leadership. It is then used as the basis for vendor RFPs, demo questions, configuration specifications, and validation acceptance criteria. It is, fundamentally, the sponsor’s document. Vendors respond to it; they do not author it.

What changes when requirements come first

When the sponsor leads with requirements, several procurement-stage dynamics shift in the sponsor’s favour.

First, the demo conversation changes. Instead of “show us what your platform does,” the question becomes “here are 12 specific scenarios drawn from this trial; walk us through how your platform handles each.” Vendors are forced into the trial’s frame, not their own. Strengths and constraints surface in context. The sponsor’s evaluation team is no longer scoring marketing; it is scoring fit.

Second, the contracting conversation changes. The sponsor’s requirements become the basis for the SOW, not the vendor’s standard scope. The vendor’s deliverables are framed around the sponsor’s needs. Validation acceptance criteria are pre-defined. Change control is anchored to sponsor-defined baselines. The contract is harder to negotiate at the start. It is significantly easier to manage later.

Third, the oversight evidence is structurally easier. The sponsor’s requirements document becomes the spine of the validation package. Each requirement maps to a vendor deliverable, an acceptance test, and a piece of operational evidence. The sponsor’s oversight records build naturally as the trial progresses. By the time an inspector or auditor asks for evidence, the records have been accumulating in the right structure for months.

Why sponsors skip this

The procurement timeline is the usual culprit. A sponsor team is told the trial needs to start in 90 days and the eCOA has to be selected, contracted, and configured before then. There is no time to author a 60-page requirements document. So the team goes to the demos and chooses fast.

This timeline pressure is real. It is also frequently self-inflicted. The sponsor’s leadership set the start-date target without budgeting for the requirements work, because the requirements work is invisible until it is missing. The cost of skipping it shows up later, after the leaders who set the target have moved on to the next milestone.

The other reason sponsors skip this is internal capability. Authoring trial-level requirements documents requires people who can read the protocol, the regulatory framework, the data flow, and the operational reality, and synthesise them into a coherent specification. This is a senior skill set. Many sponsor teams do not have it on staff; many do, but those people are already over-allocated. The work then moves to a CRO or to the vendor, both of whom have a perspective and an interest, and neither of whom is the right author for a sponsor specification.

The minimum viable version

If 60 pages and several weeks is not realistic, there is a minimum viable version. It is not a substitute for the full discipline; it is an intermediate posture that prevents the worst failure modes.

Author a 5 to 10 page document that articulates: the trial’s data flow at a high level, the regulatory frameworks that apply, the most critical sponsor oversight points (typically 4 to 8), the integration touchpoints with other systems, and the top 10 to 15 trial-specific scenarios that the chosen platform must support. Use this as the basis for vendor demos and SOW negotiations. Expand it into the fuller specification during implementation, ideally before validation begins.

This minimum viable version is not the right answer. It is the right compromise. It moves the sponsor’s procurement-stage posture from “evaluating vendor demos” to “evaluating vendor fit against trial-specific scenarios,” which is a meaningful shift even at limited document depth.

The closing question

For your most recent clinical technology selection, was the decision document anchored in your trial’s specifications, authored by your team, signed off by your quality leadership? Or was it anchored in a vendor demo and a feature comparison? The two artefacts produce very different downstream evidence. The work is to know which one you have, and to author the other before the next selection.

Continue reading: Data Integrity Is a Commercial Risk, the perspective that makes the cost of weak procurement decisions explicit. The Regulator-Vendor Gap for the structural context. All four perspectives in the insights archive. To bring this perspective to your team or stage, see media and booking.

Frequently asked

The post Requirements before selection. Why the procurement sequence matters more than the platform. appeared first on Lauren Alani.

“ICH GCP E6(R3) didn’t ask vendors to raise their standards. It asked sponsors to verify that they had.”

Lauren Alani

Regulators write to sponsors. They send inspection notices to sponsors. They ask sponsors for documentation. They publish guidance addressed to sponsors. The vendor ecosystem (eCOA, ePRO, EDC, eTMF, IRT, wearables, AI tools, real-world data platforms) sits one layer down. Vendors operate within whatever specifications a sponsor sets, but they are not directly accountable to the regulator for the trial’s compliance posture.

This is a structural fact. It is not an accident or an oversight in the regulatory framework. It is the design. The regulator’s enforcement reach is the sponsor; the sponsor’s contractual reach is the vendor; the vendor’s reach is the system it builds. In a clean line of accountability, that chain works. In practice, it leaks. The leak is what I call the regulator-vendor gap, and it is structural.

What “the gap” actually looks like

The regulatory framework, particularly ICH GCP E6(R3), EMA’s reflection paper on computerised systems, and FDA 21 CFR Part 11, articulates expectations the sponsor must meet around data integrity, system validation, audit trail, and electronic records. These expectations are written for the sponsor. They are not written for the vendor.

The vendor’s market response is to claim alignment. “Our platform is 21 CFR Part 11 compliant.” “Our validation package supports GCP.” “We follow ALCOA+ principles.” These statements are commercial claims. They may also be entirely accurate. What they are not is the sponsor’s evidence. They are inputs to it.

The danger of that assumption is that sponsors treat vendor compliance claims as if they were sponsor compliance evidence. They are not. Inspectors do not ask the vendor; they ask the sponsor. The sponsor has to produce records that demonstrate the vendor’s claims have been verified, configured to fit the specific trial, and integrated into a data lifecycle the sponsor can defend.

Why the gap exists

It is tempting to read this as a regulatory failure: surely vendors should be directly accountable to regulators? In practice, it would be unworkable. Vendors serve many sponsors, across many regulatory jurisdictions, building many configurations. A regulator cannot oversee every commercial product configuration in every trial. The sponsor is the right unit of regulatory enforcement because the sponsor is the entity that owns the trial, owns the protocol, owns the asset under development, and is the legal person under regulatory duty.

The gap is therefore a feature of the framework, not a bug in it. The framework relies on the sponsor to translate regulatory expectations into vendor specifications, to verify the vendor’s response, and to hold the resulting records for inspection. When that translation work is done well, the chain of accountability holds. When it is delegated to vendors and CROs without sponsor-level evidence, the chain leaks.

How sponsors absorb the gap by default

Sponsors absorb the gap whether or not they recognise it. There are three common patterns I see across clinical-stage biotechs and small to mid-cap pharma.

Pattern 1: Vendor-led specifications

The sponsor selects a vendor, runs through the vendor’s standard discovery process, and accepts the vendor’s standard configuration. The vendor’s framework becomes the trial’s de facto specification. This is fast and feels efficient. It also means the sponsor’s regulatory expectations were never explicitly translated into the trial’s specifications. The translation step (regulatory → vendor-facing requirements) was skipped. When inspectors later ask “show me how your trial-specific requirements were derived from regulatory expectations and verified,” there is no document.

Pattern 2: Trust-by-tier

The sponsor selects a Tier 1 vendor or a Tier 1 CRO and treats the brand as substitute evidence. The thinking goes: a Tier 1 has been audited many times, must therefore be compliant, therefore the sponsor’s compliance burden is reduced. Inspectors do not buy this reasoning. They ask the same questions of every sponsor, regardless of who the vendors are. The Tier 1 brand is a useful input; it is not a discharge of accountability.

Pattern 3: Compliance by certification

The sponsor accepts vendor certifications (ISO 27001, SOC 2, the vendor’s own validation package) as proof of compliance. Certifications are evidence of process maturity. They are not evidence that the specific trial’s data integrity requirements have been met. SOC 2 does not validate that a sponsor’s eCOA configuration captures the right data points in the right format. ISO 27001 does not validate that an EDC system enforces the protocol’s edit checks. These are sponsor-specific verification questions; certifications are a generic backdrop.

Closing the gap

The work of closing the regulator-vendor gap is sponsor-side translation, executed in sequence, with the output captured in sponsor-held records.

Step one is to articulate, in sponsor-owned documentation, what each regulatory expectation requires of this specific trial. Not what it requires of vendors generically; what it requires of this sponsor’s this trial. The output is a set of trial-level regulatory requirements, sponsor-authored, sponsor-signed.

Step two is to translate those regulatory requirements into vendor-facing specifications. The translation is sponsor work. It produces user requirement specifications, configuration documents, and validation acceptance criteria that the vendor will then deliver against. The sponsor sets the bar; the vendor meets the bar; the sponsor verifies that the bar was met. The translation document, signed by the sponsor, is the bridge across the gap.

Step three is verification. The vendor produces validation outputs, configuration evidence, and operational artefacts. The sponsor reviews them against the trial-level specifications. Acceptance is documented in sponsor-held records. Where the vendor’s output falls short, the sponsor escalates and resolves. Where it meets specification, the sponsor accepts in writing. This document trail is what closes the regulator-vendor gap from the sponsor side.

Why this matters now

ICH GCP E6(R3) raised the bar on sponsor oversight expectations in 2023, with progressive enforcement through 2026. EMA’s guidance on computerised systems is increasingly specific. FDA inspections of clinical-stage assets are increasingly attentive to electronic records and audit trails. The structural gap was always there. The regulatory attention to whether sponsors have closed it is intensifying.

Sponsors who continue to absorb the gap by default are not exposed catastrophically; they are exposed cumulatively. Findings are usually moderate. Patterns of findings are not. An accumulation of “sponsor failed to demonstrate oversight” observations across trials, sites, or programmes shows up as a quality system weakness, and that observation can drag valuation, partnership terms, and submission timing.

The closing question

Look at one of your active trials. Find the document that translates the trial’s regulatory expectations into vendor-facing specifications, in your own organisation’s voice, signed by your own quality leadership. If that document does not exist, it is the gap. The work is to author it before someone else asks why it was missing.

Continue reading: Requirements Before Selection for the procurement-stage discipline that prevents the gap from forming in the first place. Accountability Cannot Be Delegated for the underlying principle. All four perspectives in the insights archive. About Lauren for the working method.

Frequently asked

The post The regulator-vendor gap is structural. Sponsors absorb it by default. appeared first on Lauren Alani.

“Ultimately, the sponsor’s name is on the submission. The vendor’s name is not.”

Lauren Alani

An inspector arrives at a sponsor’s office to review a closed-out Phase 2 study. The sponsor’s clinical operations lead opens the meeting confidently. The systems were built and validated by the eCOA vendor. The trial was run by a Tier 1 CRO. The data management plan was authored jointly. Everything is documented somewhere.

The inspector asks one question: where is your evidence that the sponsor exercised oversight of the data flow from electronic source through to submission database?

The room goes quiet. The vendor’s validation package is in a SharePoint folder. The CRO’s monitoring reports are in another folder. The data management plan references both. But the sponsor’s own oversight evidence, the documentation that demonstrates the sponsor saw the data move, asked the right questions, and accepted the answers, is thin. There are emails. There are meeting minutes. There is no structured oversight record.

The MSA assigned the vendor to build and validate. The CRO services agreement assigned trial conduct. The data management plan assigned data management. The protocol was signed by the sponsor. And under ICH GCP E6(R3), the sponsor is responsible for the conduct of the trial regardless of which activities are delegated. That responsibility does not transfer with a contract. It cannot be assigned away.

The MSA myth

I have lost count of the number of sponsor leaders who, when pressed, will say something like: “we paid the vendor to validate the system, that’s their job, they have ISO certifications.” Or: “the CRO is a Tier 1, they handle compliance, that’s why we chose them.” Both statements are factually accurate. Neither is regulatorily sufficient.

The danger of that assumption is that ultimately, when an inspector or an auditor asks for evidence, regulators do not write to the vendor. They do not write to the CRO. They write to the sponsor. The sponsor is the holder of the IND, the CTA, or the regulatory dossier. The sponsor is the legal person under regulatory scrutiny. And the sponsor is the entity that has to demonstrate, with documentation, that the trial’s data is fit for purpose.

Contracts are mechanisms for delegating execution and allocating commercial risk. They are not mechanisms for transferring regulatory accountability. The drafting language used in master service agreements (the indemnities, the warranties, the SLAs) creates the comforting illusion that someone else is now holding the bag. Read carefully, the language almost always reserves regulatory accountability with the sponsor. Because the regulator does not recognise any other holder.

Where the assumption shows up in practice

The MSA myth has three common operational expressions. Each looks sensible in isolation. Together they produce inspection findings.

1. “The vendor’s system is validated”

Vendor validation is a real thing. It documents that the system, as built, performs to its documented requirements. What it does not do is validate the sponsor’s configuration of that system in the context of this specific trial, mapped against this specific protocol. Configuration is sponsor work. The risk-based validation strategy that frames it is sponsor work. The user acceptance testing that confirms the configured system meets the trial’s intended use is sponsor work.

Inspectors will accept that the platform is vendor-validated. They will then ask to see the sponsor’s evidence of fit-for-purpose configuration, validation oversight, and acceptance. If that evidence is “the vendor told us it was fine,” the finding is already written.

2. “The CRO is handling that”

CROs run trials. They write data management plans. They monitor sites. They produce listings, queries, and clean databases. All of this is delegated work. Per ICH GCP E6(R3) §5.2, the sponsor remains responsible for the quality and integrity of trial data even when the trial is conducted by a contract organisation. The standard is explicit: the sponsor’s quality system has to provide oversight of the delegated parties.

“The CRO is handling that” is not oversight. Oversight is a documented, sponsor-led activity. It produces sponsor-held records. It involves the sponsor asking specific questions, receiving specific answers, evaluating those answers against the protocol and regulatory requirements, and either accepting or escalating. If a sponsor cannot show inspectors that record, the CRO’s good work does not save the sponsor’s position.

3. “We trust them”

Trust is necessary. Trust is also a leadership intuition. It is not an audit-defensible position. The regulator does not ask whether the sponsor trusted the vendor; the regulator asks whether the sponsor verified what the vendor produced, in a structured way, with documentation. Trust is what makes the partnership functional. Verification is what makes the trial defensible.

What the regulators say

ICH GCP E6(R3) §5.2 states the sponsor is “responsible for ensuring oversight” of any trial-related duties and functions transferred to a service provider. EMA’s reflection paper on GCP compliance of clinical trials with computerised systems reinforces that the sponsor must implement processes for ongoing oversight of the use of computerised systems. FDA’s 21 CFR Part 11 requirements apply to the sponsor’s records, not the vendor’s. The position is consistent across major regulatory frameworks: delegation does not equal transfer.

This is not a recent shift. It has been the regulatory position for decades. What has shifted is how often inspectors are now asking specifically for the sponsor’s oversight evidence, in a form that demonstrates active engagement with the data lifecycle. The bar has been raised, and the spotlight is now consistently on the sponsor’s records, not on the vendor’s brochure.

What sponsors can do instead

The shift is from procurement-led to oversight-led thinking. Procurement asks: did we buy a validated system? Oversight asks: can I demonstrate that this system, configured for this trial, produces data we can defend at inspection? The answers are different, and they live in different documents.

A risk-based approach to oversight starts with the trial-level requirements, not the vendor’s documentation. It asks: where does data enter our trial? Through which systems? Where is it transformed? Where does it land? At each handoff, what could go wrong, and what evidence will we hold to demonstrate it did not? The answer to that last question is the sponsor’s oversight record. It is the sponsor’s, not the vendor’s, not the CRO’s.

Practically, this looks like a small set of repeating disciplines: a risk register that is sponsor-owned and sponsor-reviewed; a data flow map that the sponsor signed off on, not just received; user requirement specifications that translate the protocol’s needs into vendor-facing language; a validation oversight plan that says what the sponsor will check, when, and to what threshold; and a documented review cadence that produces records when (not if) inspectors want them.

None of this is exotic. None of it is expensive in absolute terms. It is, however, a different posture than “we’ve engaged a Tier 1 CRO and a validated vendor.” It is the posture of a sponsor that has decided to retain accountability deliberately, structurally, and documentably. It is the only posture that holds up.

The closing question

If an inspector arrived at your office tomorrow and asked for your sponsor-held evidence of oversight across the clinical data lifecycle for your most active trial, where would you start? If the first answer involves “we’ll have to ask the vendor” or “the CRO has that,” the gap is the answer. The work is to close it before someone else asks the question.

Continue reading: The Regulator-Vendor Gap, the structural context that makes this accountability question harder than it should be. For all four perspectives, see the insights archive. To bring this perspective to a stage, podcast, or panel, see the media and booking page.

Frequently asked

The post Accountability cannot be delegated. The sponsor signed the protocol. appeared first on Lauren Alani.